Resveratrol administration did not modify muscle Slc2a4/GLUT4 expression in comparison to insulin alone, showing that, as adjunctive therapy in T1D, this compound does not improve glucose clearance by skeletal muscle. This evidence concerns the gene SLC2A4 and type 1 diabetes mellitus.